Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
A Mwema, GG Muccioli, A Des Rieux - Journal of Controlled Release, 2023 - Elsevier
Disorders of the central nervous system (CNS), such as multiple sclerosis (MS) represent a
great emotional, financial and social burden. Despite intense efforts, great unmet medical …
great emotional, financial and social burden. Despite intense efforts, great unmet medical …
Involvement of TLR2–TLR4, NLRP3, and IL-17 in pain induced by a novel Sprague-Dawley rat model of experimental autoimmune encephalomyelitis
AJ Kwilasz, MA Clements, TA Larson… - Frontiers in Pain …, 2022 - frontiersin.org
Up to 92% of patients suffering from multiple sclerosis (MS) experience pain, most without
adequate treatment, and many report pain long before motor symptoms associated with MS …
adequate treatment, and many report pain long before motor symptoms associated with MS …
Current non-invasive strategies for brain drug delivery: overcoming blood–brain barrier transport
X Zheng, J Yang, Y Hou, Y Fang, K Wu, Y Song… - Molecular Biology …, 2024 - Springer
Background The blood-brain barrier (BBB) is a complex and dynamic structure that serves
as a gatekeeper, restricting the migrations of most compounds and molecules from blood …
as a gatekeeper, restricting the migrations of most compounds and molecules from blood …
The sphingosine 1‐phosphate analogue, FTY720, modulates the lipidomic signature of the mouse hippocampus
DM Magalhães, NA Stewart, M Mampay… - Journal of …, 2024 - Wiley Online Library
The small‐molecule drug, FTY720 (fingolimod), is a synthetic sphingosine 1‐phosphate
(S1P) analogue currently used to treat relapsing–remitting multiple sclerosis in both adults …
(S1P) analogue currently used to treat relapsing–remitting multiple sclerosis in both adults …
Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis
P Papakyriakopoulou, E Balafas… - Pharmaceutical …, 2024 - Springer
Background Fingolimod hydrochloride (FH) has emerged as a vital medication for managing
Multiple Sclerosis (MS). Despite its high oral bioavailability of 93%, it is plagued by slow oral …
Multiple Sclerosis (MS). Despite its high oral bioavailability of 93%, it is plagued by slow oral …
Taking Advantages of Blood–Brain Barrier to Optimize Delivery of Drugs in Central Neurological Conditions
Y Hou, Y Fang, K Wu, Y Song, K Liu, J Zhu… - Available at SSRN … - papers.ssrn.com
The blood-brain barrier (BBB) is a complex and dynamic structure that serves as a
gatekeeper, restricting the migrations of most compounds and molecules from blood into the …
gatekeeper, restricting the migrations of most compounds and molecules from blood into the …